The aim of this study was to examine the resistance genes in clinical isolates which 35 produced IMP-6 type metallo-β-lactamase lactamase (MBL) and had mildly reduced 36 susceptibilities to levofloxacin and/or amikacin. The inoculum size effect was also 37 assessed. A total of 14 Enterobacteriaceae isolates (2 Escherichia coli and 12 Klebsiella 38 pneumoniae) which produced IMP-6 MBL, and had mild increases in their MICs for 39 levofloxacin and amikacin were examined. Thirteen out of 14 isolates harbored 40 CTX-M-2, with the remaining isolate co-harboring CTX-M-2 and CTX-M-1 as ESBLs. 41
respectively. No inoculum size effect was seen for levofloxacin. Four strains harbored 48 qnr genes and 2 strains harbored qnr genes and QRDR mutations concurrently. bla 49 positive Enterobacteriaceae with mildly reduced susceptibilities to levofloxacin and/or 50 amikacin also harbored at least one plasmid-mediated drug resistance gene. These 51 8 All isolates were confirmed bla IMP-6 positive by both PCR and DNA sequencing 123 (15), and we performed additional PCR testing for bla VIM , bla KPC , bla NDM , and 124 bla OXA-48-like to assess additional carbapenemase genes (16) . We also performed PCR to 125 detect the presence of extended-spectrum β-lactamases (ESBLs; TEM, SHV, CTX-M, 126
and OXA) (17) . The presence of plasmid-mediated quinolone resistance genes (qnrA, 127 qnrB, qnrC, qnrD, and qnrS), efflux pump genes (qepA and oqxAB), aac(6′)-Ib and 128
aac(6′)-Ib-cr was also assessed by PCR (18-21). 129
The presence of aminoglycoside-modifying enzymes (aph(3′)-VI and 130
ant(4′′)-IIa), which have been reported to reduce susceptibility to amikacin and have been 131 detected in Enterobacteriaceae, was also assessed by PCR using specific primers (22, 23) . 132
The QRDRs in gyrA and parC were amplified as previously described (24,25) and were 133 sequenced to assess any co-existing chromosomal mutations (26) . 134
135

Antimicrobial susceptibility testing 136
The minimum inhibitory concentrations (MICs) of levofloxacin, amikacin, 137 imipenem, and meropenem, were evaluated by the agar dilution method at a standard 138 inoculum size according to the CLSI guidelines (27). We also evaluated the MICs of 139 these drugs for the strains using 10-and 100-fold of the colony forming units (CFU) in the9 standard inoculum. All results were interpreted according to the CLSI criteria describing 141 in vitro susceptibility (14). We defined that an inoculum size effect was significant if the 142
MICs of antibiotics showed  4-fold increase at a 100-fold of the inoculum size compared 143 with the standard inoculum size. 144
145
Conjugation experiments 146
Conjugation experiments were performed using the broth mating technique with 147 sodium azide resistant E. coli J53 and E. coli NR 3500 containing the gyrA mutation 148
Ser83Phe. E. coli NR3500 were obtained from E. coli J53 using an LB agar plate 149 containing levofloxacin (MIC; 0.125 µg/mL). Transconjugants were selected on LB agar 150 plates containing sodium azide (100 µg/mL), and cefpodoxime (8 µg/mL). Transfer of 151 drug resistant genes (IMP-6, CTX-M-1, CTX-M-2, qnrB, qnrS, oqxA, oqxB, and 152 aac(6′)Ib-cr) was confirmed by the PCR method described above. 153
Results
154
Antibiotic resistant genes 155
For carbapenemase genes, none of the tested isolates harbored other MBL genes 156
besides bla . For ESBL genes, CTX-M-2 was detected in all isolates, and one isolate 157 co-harbored both CTX-M-2 and CTX-M- The results of the antibiotic susceptibility tests are shown in Table 1 . For all the 170 antibiotics tested, the MIC values of all the isolates at 10-fold the standard inoculum size11 were equal to or higher than those using the standard inoculum, and those at 100-fold the 172 standard inoculum size were equal to or higher than those using 10-fold the standard 173 inoculum size. Inoculum size effects were observed in all isolates for meropenem (MIC 174 range; 1-4 to 16-128 µg/mL), 13 for imipenem (MIC range; 0.063-0.5 to 0.5-2 µg/mL), 175 7 for levofloxacin (MIC range; 0.5-4 to 1-16 µg/mL) , and 3 for amikacin (MIC range; 176 2-16 to 2-32 µg/mL). Based on the CLSI breakpoint in M100-S25 at the standard 177 inoculum size, all isolates showed susceptibility to amikacin and imipenem. Two isolates 178 (14.3%) and 6 isolates (42.9%) were not susceptible to levofloxacin and meropenem, 179 respectively. On the other hand, at 100-fold the standard inoculum size, 2 isolates, 8 180 isolates, 9 isolates were found to not be susceptible to amikacin, levofloxacin, and 181 imipenem, respectively. All isolates were resistant to meropenem at 100-fold the standard 182 inoculum size. 183
184
Conjugation experiments 185
Conjugation experiments were performed successfully with 8 isolates and 11 186 strains were obtained ( Table 2 ). The recipient strain (E. coli J53, NR3500) did not show 187 an inoculum size effect and was susceptible to all of the antibiotics we tested with or 188 without the presence of QRDR mutation. Eleven isolates (100%), 8 strains (72.7%), and 112 strain showed inoculum size effects for meropenem, imipenem, and amikacin, 190
respectively. In addition, based on our definition, no inoculum size effect for levofloxacin 191 was seen in the conjugant strains. In these strains, 4 strains harbored qnr genes, and 2 192 strains harbored both qnr genes and QRDR mutation concurrently. Thus, our experiments 193
showed that the inoculum size effects for carbapenems were apparent with IMP-6 type 194 carabapenemase, and that these effects were greater for meropenem than for imipenem. 195
In addition, the qnrS and qnrB genes did not provide an apparent inoculum size effect for CFU/mL per MIC of 10 5 CFU/mL) (9). However, they also showed that the inoculum size 215 effects for quinolone were significant for laboratory strains which did not harbor acquired 216 quinolone resistance genes. Thus, qnr genes have only a small impact on the inoculum 217 size effects for levofloxacin. Rice reported that resistance to quinolone arises as the result 218 of a combination of various resistance mechanisms, and that the acquisition of qnr genes 219 increase the MIC but not to a level that would be considered clinically resistant (28). 220
Further studies should be performed to identify other factors that could explain this 221 difference. 222
One experimental strain (NR 379 and NR 3500), which harbored the qnrB gene 223 and gyrA mutation, showed susceptibility to levofloxacin based on CLSI breakpoint 224 M100-S25, but was resistant based on the EUCAST clinical breakpoint ver. 8.1 at 225 100-fold the inoculum size (29). Therefore, we should not completely ignore qnr genes if 226 the strain shows a decreased susceptibility to levofloxacin in the setting of a huge level of 227 organismal infection (e.g. an abscess or in bacteremia). 228
Presently, a combination therapeutic strategy is recommended for 229 carbapenemase-producing Enterobacteriaceae infections (1-2, 30 ). reported that most pathogens have been confirmed to produce IMP-type carbapenemases, 238 and some cases have been successfully treated with quinolone monotherapy as a 239 definitive therapy based on drug susceptibility tests (7). However, in the present study the 240 isolates did not show resistance to levofloxacin, amikacin, and carbapenems based on the 241 CLSI definition, and the MICs of some isolates turned to be high enough to be resistant to 242 these drugs especially meropenem (the MIC for all isolates was  16 µg/mL) at 100-fold 243 15 the standard inoculum size. This suggests that in the context of a clinical infection, these 244 pathogens may fail to be treated despite the use of "susceptible" drugs identified by the 245 usual methods. In fact, it has been reported that 55.6% of infectious cases caused by 246 KPC-type carbapenemase producing K. pneumoniae, which showed susceptibility in 247 automated drug susceptibility tests, failed to be treated by imipenem or meropenem (31). 248
In conclusion, bla IMP-6 positive Enterobacteriaceae, with a mild MIC elevation 249 for levofloxacin and/or amikacin, harbored at least one plasmid-mediated drug resistance 250 gene, other than ESBLs, and carbapenemase at the same time. Furthermore, these isolates 251 showed inoculum size effects for levofloxacin, amikacin, and carbapenems (especially 252 for meropenem compared with imipenem). The decrease in the MICs for carbapenems 253 was thought to be mainly due to IMP-6 type metallo-β-lactamase, however qnr had a 254 small effect on the decrease in the MIC for levofloxacin. 
